Bevacizumab is increasingly used in combination with chemotherapy for treatment of unresectable non-small cell lung cancer. The aim of this report is to underline possible risks associated with this otherwise well-tolerated drug.
Publication
Investigational new drugs, 2009, Vol 27, Issue 2, p184